ID
17655
Beskrivning
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Länk
https://clinicaltrials.gov/ct2/show/NCT00373425
Nyckelord
Versioner (2)
- 2016-08-01 2016-08-01 -
- 2016-09-27 2016-09-27 -
Uppladdad den
27 september 2016
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Prevention and Treatment of Skin, Hair and Nail Reactions, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Beskrivning
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Beskrivning
Record all topical creams, gels, oral or IV medications, and/or other interventions used to prevent and treat skin, hair and nail reactions (includes rash, skin fissures, nail and hair changes, etc) due to study drug administration. Moisturizers and sunscreens used to prevent and treat skin reactions should be recorded on the Moisturizers and Sunscreens CRF page.
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [1,2]
- C0221743 (Skin reaction)
- SNOMED
- 251348006
- UMLS CUI [2,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [2,2]
- C0018500 (Hair Diseases)
- SNOMED
- 279425004
- UMLS CUI [3,1]
- C0087111 (Therapeutic procedure)
- SNOMED
- 277132007
- LOINC
- LP21090-3
- UMLS CUI [3,2]
- C0234909 (Nail changes)
- SNOMED
- 416596008
Beskrivning
Indication Prophylaxis
Datatyp
boolean
Alias
- UMLS CUI [1,1]
- C3146298 (Indication)
- UMLS CUI [1,2]
- C0199176 (Prophylactic treatment)
- SNOMED
- 360271000
Beskrivning
Drug Administration Route
Datatyp
integer
Alias
- UMLS CUI [1]
- C0013153 (Drug Administration Routes)
- SNOMED
- 410675002
- LOINC
- LP40261-7
Beskrivning
Drug Administration Route
Datatyp
text
Alias
- UMLS CUI [1]
- C0013153 (Drug Administration Routes)
- SNOMED
- 410675002
- LOINC
- LP40261-7
Beskrivning
Specific Indication should be reported on the Adverse Event (Including Baseline Signs/Symptoms) CRF page, unless the intervention was given as a prophylaxis.
Datatyp
integer
Alias
- UMLS CUI [1]
- C3146298 (Indication)
Beskrivning
Indication
Datatyp
text
Alias
- UMLS CUI [1]
- C3146298 (Indication)
Beskrivning
Date Started
Datatyp
date
Alias
- UMLS CUI [1]
- C3173309 (Date treatment or therapy started)
- LOINC
- LP262646-5
Beskrivning
Date Stopped
Datatyp
date
Alias
- UMLS CUI [1]
- C1531784 (Date treatment stopped)
- SNOMED
- 413947000
Beskrivning
Date Stopped
Datatyp
boolean
Alias
- UMLS CUI [1]
- C1531784 (Date treatment stopped)
- SNOMED
- 413947000
Similar models
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0199176 (UMLS CUI [1,2])
Inga kommentarer